CERILLIANT™ Suvorexant-D6 Solution, 100 μg/mL in Methanol, Sold by MilliporeSigma™ Supelco™

Description

Suvorexant, sold under the trade name Belsomra, is a medication for the treatment of insomnia, approved for sale by the U.S. Food and Drug Administration (FDA) in 2014. The U.S. Drug Enforcement Administration (DEA) has scheduled this substance as controlled substance, as it may lead to physical or psychological dependence. This stable-labeled internal standard is suitable for use in quantitation of suvorexant levels by GC/MS or LC/MS for applications in clinical toxicology, therapeutic drug monitoring or urine drug testing.